Erste Asset Management GmbH Acquires New Stake in United Therapeutics Co. (NASDAQ:UTHR)

Erste Asset Management GmbH acquired a new position in shares of United Therapeutics Co. (NASDAQ:UTHR) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 45,266 shares of the biotechnology company’s stock, valued at approximately $16,224,000. Erste Asset Management GmbH owned about 0.10% of United Therapeutics at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in UTHR. ClariVest Asset Management LLC raised its stake in United Therapeutics by 120.0% during the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after buying an additional 42 shares during the period. V Square Quantitative Management LLC bought a new stake in shares of United Therapeutics during the second quarter valued at approximately $30,000. Innealta Capital LLC acquired a new position in shares of United Therapeutics during the second quarter worth approximately $33,000. USA Financial Formulas bought a new position in shares of United Therapeutics in the 3rd quarter worth $33,000. Finally, Brooklyn Investment Group acquired a new stake in United Therapeutics in the 3rd quarter valued at $33,000. 94.08% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at United Therapeutics

In related news, Director Nilda Mesa sold 224 shares of the company’s stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $412.28, for a total transaction of $92,350.72. Following the sale, the director now directly owns 5,783 shares in the company, valued at approximately $2,384,215.24. This represents a 3.73 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $372.75, for a total transaction of $3,727,500.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at approximately $960,576.75. This trade represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 127,227 shares of company stock worth $47,398,820. 11.90% of the stock is owned by company insiders.

United Therapeutics Stock Down 2.0 %

UTHR opened at $370.49 on Monday. The company’s 50-day moving average price is $367.77 and its two-hundred day moving average price is $335.65. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $417.82. The stock has a market cap of $16.54 billion, a price-to-earnings ratio of 16.27, a PEG ratio of 1.08 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, beating the consensus estimate of $6.16 by $0.23. The business had revenue of $748.90 million during the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. United Therapeutics’s revenue was up 22.9% compared to the same quarter last year. During the same period in the prior year, the company earned $5.38 earnings per share. As a group, sell-side analysts anticipate that United Therapeutics Co. will post 25.22 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on UTHR. Jefferies Financial Group boosted their target price on shares of United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a research report on Monday, September 23rd. LADENBURG THALM/SH SH boosted their price objective on United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. Wells Fargo & Company upped their price target on United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a report on Tuesday, August 20th. Finally, Oppenheimer raised their price objective on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. One research analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $370.86.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.